We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.

Delisted

AVEO was delisted on the 19th of January, 2023.

68 hedge funds and large institutions have $41.2M invested in AVEO Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 25 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

3% less funds holding

Funds holding: 7068 (-2)

31% less capital invested

Capital invested by funds: $59.9M → $41.2M (-$18.7M)

44% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 25

79% less call options, than puts

Call options by funds: $6K | Put options by funds: $28K

Holders
68
Holders Change
-2
Holders Change %
-2.86%
% of All Funds
1.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
15
Increased
14
Reduced
25
Closed
16
Calls
$6K
Puts
$28K
Net Calls
-$22K
Net Calls Change
-$22K
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
51
Morgan Stanley
New York
$34K -$221K -12,286 -84%
NCCM
52
Nine Chapters Capital Management
New Jersey
$30K +$13.5K +750 +60%
TRCT
53
Tower Research Capital (TRC)
New York
$29K +$35K +1,950 New
Susquehanna International Group
54
Susquehanna International Group
Pennsylvania
$23K +$4.15K +231 +18%
EWM
55
Evercore Wealth Management
New York
$19K
FCI
56
Financial Counselors Inc
Kansas
$19K +$23.3K +1,300 New
JMPWA
57
JP Morgan Private Wealth Advisors
California
$17K +$20.1K +1,118 New
EWM
58
Edge Wealth Management
New York
$15K
Bank of America
59
Bank of America
North Carolina
$4K -$7.26K -404 -59%
U
60
UBS
Switzerland
$2K -$37.1K -2,067 -95%
Barclays
61
Barclays
United Kingdom
$2K +$1.6K +89 +68%
PCM
62
Prelude Capital Management
New York
$2K +$2.15K +120 New
CFA
63
CT Financial Advisors
Pennsylvania
$1.16K +$1.44K +80 New
Ameriprise
64
Ameriprise
Minnesota
$1K
Wells Fargo
65
Wells Fargo
California
$1K
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$914 -$862 -48 -39%
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$55 -$11.8K -655 -15%
MAM
68
MPM Asset Management
Massachusetts
-$2.51M -137,212 Closed
Fidelity Investments
69
Fidelity Investments
Massachusetts
-$1.6M -87,046 Closed
BCM
70
Bridgeway Capital Management
Texas
-$1.06M -58,000 Closed
VAM
71
Visium Asset Management
New York
-$736K -40,000 Closed
Millennium Management
72
Millennium Management
New York
-$623K -34,029 Closed
RA
73
Royce & Associates
New York
-$402K -21,858 Closed
KFC
74
Klingenstein Fields & Co
New York
-$251K -13,740 Closed
AQR Capital Management
75
AQR Capital Management
Connecticut
-$175K -9,520 Closed

AVEO Hedge Fund Activity: Q1 2014 in Review

68 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2014, worth a combined $41.2M — down 31% from $59.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AVEO and 15 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 14 added.

The largest buyer was SAC Capital Advisors, opening a new position worth an estimated $898K. The largest seller was MPM Asset Management, exiting entirely with an estimated $2.51M sold.

  • 68 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2014, down from 70 in Q4 2013.
  • Funds reported $41.2M of AVEO Pharmaceuticals, Inc. stock for Q1 2014, down 31% quarter-over-quarter.
  • 15 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2014 and 16 closed out, a net change of -1 holder.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2014 was SAC Capital Advisors, an estimated $898K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q1 2014 was MPM Asset Management, an estimated $2.51M sold.

Based on aggregated 13F filings for Q1 2014.